Factor VIII/IX claims will not be pursued by federal insurers, according to DoJ/defendants agreement.
Executive Summary
FACTOR VIII/IX CLAIMS BY FEDERAL INSURERS WILL NOT BE PURSUED, according to an April 30 letter from the defendants in the hemophilia/HIV class action suit to Chicago federal court Judge John Grady. The Department of Justice, which represented federal insurance programs, is accepting the payment of the $640 mil. settlement to hemophilia patients who received HIV-tainted blood ("The Pink Sheet" March 24, p. 11). The government insurers, which may have paid for some of the treatments, will not seek to recover money from the settlements.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth